Schrodinger Inc. (NASDAQ: SDGR) reported Q2 EPS of ($0.49), $0.16 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $29.8 million versus the consensus estimate of $29.88 million.

GUIDANCE:

Schrodinger Inc. sees FY2021 revenue of $124-142 million, versus the consensus of $138.8 million.

• As of August 12, 2021, Schrödinger continues to expect total revenue to range from $124 million to $142 million, with software revenue expected to range from $102 million to $110 million and drug discovery revenue expected to range from $22 million to $32 million for the fiscal year ending December 31, 2021. Additional details are as follows:
• Schrödinger expects the majority of anticipated second half software revenue growth to occur in the fourth quarter of 2021.
• Drug discovery revenue can be highly variable quarter to quarter based on the timing of potential milestones related to collaborative agreements.
• Schrödinger continues to aggressively fund R&D to advance its technology and drug discovery pipeline. The company continues to expect operating expense growth to be higher than the 42 percent annual growth rate reported in 2020 and expects software gross margin to be lower than the 81 percent reported in 2020.

For earnings history and earnings-related data on Schrodinger Inc. (SDGR) click here.